EMAIL THIS PAGE TO A FRIEND

Oncogene

Toward a therapeutic reduction of imatinib refractory myeloproliferative neoplasm-initiating cells.


PMID 24240679

Abstract

Myeloproliferative neoplasms (MPNs) such as chronic myelogenous (CML) and chronic myelomonocytic leukemias (CMML) are frequently induced by tyrosine kinase oncogenes. Although these MPNs are sensitive to tyrosine kinase inhibitors such as imatinib, patients often relapse upon withdrawal of therapy. We used a model of MPN, which is induced by co-expression of the oncoproteins HIP1/PDGFβR (H/P) and AML1/ETO from their endogenous loci, to examine the mechanisms of disease development and recurrence following imatinib withdrawal. Although the MPN displayed a full hematologic response to imatinib, 100% of the diseased mice relapsed upon drug withdrawal. MPN persistence was not due to imatinib resistance mutations in the H/P oncogene or massive gene expression changes. Within 1 week of imatinib treatment, more than 98% of gene expression changes induced by the oncogenes in isolated hematopoietic stem and progenitor cells (lineage(-)Sca-1(+)c-Kit(+) immunophenotype) normalized. Supplementation of imatinib with granulocyte colony-stimulating factor or arsenic trioxide reduced MPN-initiating cell frequencies and the combination of imatinib with arsenic trioxide cured a large fraction of mice with MPNs. In contrast, no mice in the imatinib-treated control cohorts were cured. These data suggest that treatment with a combination of arsenic trioxide and imatinib can eliminate refractory MPN-initiating cells and reduce disease relapse.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

SAB1405934
Anti-HIP1 antibody produced in mouse, purified immunoglobulin, buffered aqueous solution
HPA013606
Anti-HIP1 antibody produced in rabbit, Ab2, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
HPA017964
Anti-HIP1 antibody produced in rabbit, Ab1, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB4200390
Anti-HIP1 antibody produced in rabbit, ~1.5 mg/mL, affinity isolated antibody
SAB1410628
Anti-HIP1 antibody produced in rabbit, purified immunoglobulin, buffered aqueous solution
SAB4300329
Anti-STAT5A (Ab-694) antibody produced in rabbit, affinity isolated antibody
SAB4300330
Anti-STAT5A (Ab-780) antibody produced in rabbit, affinity isolated antibody
SAB1406488
Anti-STAT5A antibody produced in mouse, purified immunoglobulin, buffered aqueous solution
SAB2102318
Anti-STAT5A antibody produced in rabbit, affinity isolated antibody
HPA027873
Anti-STAT5A antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB4502878
Anti-STAT5A antibody produced in rabbit, affinity isolated antibody
SAB4502879
Anti-STAT5A antibody produced in rabbit, affinity isolated antibody
C3250000
Cyclophosphamide, European Pharmacopoeia (EP) Reference Standard
C7H15Cl2N2O2P · H2O
WH0003092M1
Monoclonal Anti-HIP1 antibody produced in mouse, clone 1F12, purified immunoglobulin, buffered aqueous solution
SAB1404416
Monoclonal Anti-STAT5A, (N-terminal) antibody produced in mouse, clone 1B12, purified immunoglobulin, buffered aqueous solution